Merck Stock Rises on Strong Q2 Earnings and Upgraded 2026 Outlook

Merck & Co. (NYSE: MRK) shares rose in pre-market trading after the company announced second-quarter 2026 financial results that exceeded Wall Street estimates and raised its full-year revenue forecast, signaling confidence in its key growth drivers.

Earnings Beat Fueled by Keytruda and New Drugs

Merck reported stronger-than-expected performance for the second quarter, driven by robust sales from its oncology and vaccine portfolios. The results provided investors with a positive signal about the company's ability to expand its revenue base beyond its flagship cancer therapy.

Key financial highlights from the report include:

• Revenue: $16.61 billion, surpassing the consensus estimate of $16.36 billion.
• Adjusted Loss Per Share: $0.13, significantly better than the 27-cent loss analysts had anticipated.
• Keytruda Sales: The blockbuster cancer drug generated $8.37 billion, a 5% year-over-year increase and above the estimated range of $8.07 billion to $8.27 billion.

Ad

Sales of newer products also showed significant momentum. Winrevair, a treatment for a rare lung condition, saw sales jump 75% year-over-year to $588 million, while the pneumococcal vaccine Capvaxive posted 42% growth.

Upgraded Forecast and Market Impact

Buoyed by the strong quarterly performance, Merck raised its full-year 2026 revenue guidance to a range of $66.3 billion to $67.3 billion, up from its previous forecast of $65.8 billion to $67 billion. This upward revision came despite a one-time $5.7 billion charge related to its acquisition of Terns Pharmaceuticals, which impacted reported net income.

The positive earnings report and outlook drove Merck's stock up 1.3% in pre-open trading. The news reinforces investor confidence that the company's pipeline and recent product launches are successfully gaining traction, which is critical as it prepares for the U.S. patent expiration of Keytruda in 2028.